Top

Published in:

Open Access 01-12-2016 | Editorial

The paradox of the evidence about invasive fungal infections prevention

Authors: Andrea Cortegiani, Vincenzo Russotto, Santi Maurizio Raineri, Antonino Giarratano

Published in: Critical Care | Issue 1/2016

Excerpt

Invasive fungal infections (IFIs) are characterized by high morbidity and mortality in non-neutropenic critically ill patients. Attributable mortality due to Candida spp. infections ranges from about 42 to 63 % [1, 2]. Data from large observational and retrospective studies show an association between early antifungal treatment and improved survival [3, 4]. Updated clinical practice guidelines for the management of candidiasis have been recently published [5]. …

Puig‐Asensio M, Padilla B, Garnacho‐Montero J, Zaragoza O, Aguado J, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population‐based surveillance in Spain. Clin Microbiol Infect. 2014;20:O245–54.CrossRefPubMed

Kett D, Azoulay E, Echeverria P, Vincent J. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665–70.CrossRefPubMed

Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:1739–46.CrossRefPubMed

Puig-Asensio M, Pemán J, Zaragoza R, Garnacho-Montero J, Martín-Mazuelos E, Cuenca-Estrella M, et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med. 2014;42:1423–32.CrossRefPubMed

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Disease Society of America. Clin Infect Dis. 2016;62:e1-e50.

Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev. 2006;1:CD004920.PubMed

Cortegiani A, Russotto V, Maggiore A, Attanasio M, Naro AR, Raineri SM, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically il patients. Cochrane Database Syst Rev. 2016;1:CD004920.

Cornely O, Bassetti M, Calandra T, Garbino J, Kullberg B, Lortholary O, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19–37.CrossRefPubMed

The ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2000;283:1995–2002.CrossRef

10.

Schuster MG, Edwards JE, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149:83–90.CrossRefPubMed

11.

Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58:1219–26.CrossRefPubMed

12.

Knitsch W, Vincent J-L, Utzolino S, François B, Dinya T, Dimopoulos G, et al. A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis. 2015;61:1671–8.PubMedPubMedCentral

13.

Spec A, Shindo Y, Burnham CA, Wilson S, Ablordeppey EA, Beiter ER, et al. T cells from patients with Candida sepsis display a suppressive immunophenotype. Crit Care. 2016;20:15.CrossRefPubMedPubMedCentral

14.

Namikawa T, Kitagawa H, Yamatsuji T, Naomoto Y, Kobayashi M, Hanazaki K. Pre-emptive treatment of fungal infection based on plasma β-D-glucan levels after gastric surgery for gastric cancer in elderly patients. J Gastroenterol Hepatol. 2013;28:1457.CrossRefPubMed

15.

Timsit J-F, Azoulay E, Cornet M, Gangneux J-P, Jullien V, Vésin A, et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials. 2013;14:399.CrossRefPubMedPubMedCentral

16.

Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125:S3–S13.CrossRefPubMed

Title: The paradox of the evidence about invasive fungal infections prevention
Authors: Andrea Cortegiani
Vincenzo Russotto
Santi Maurizio Raineri
Antonino Giarratano
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Critical Care / Issue 1/2016
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-016-1284-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The paradox of the evidence about invasive fungal infections prevention

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Echocardiography as a guide for fluid management

The utility of biomarkers in traumatic brain injury clinical management

Intravascular versus surface cooling for targeted temperature management after out-of-hospital cardiac arrest – an analysis of the TTM trial data

Chlorhexidine bathing and health care-associated infections among adult intensive care patients: a systematic review and meta-analysis

Elevated plasma heparin-binding protein is associated with early death after resuscitation from cardiac arrest

Effect of the Cardio First Angel™ device on CPR indices: a randomized controlled clinical trial